# reload+after+2024-01-20 17:44:32.164926
address1§19900 MacArthur Boulevard
address2§Suite 550
city§Irvine
state§CA
zip§92612
country§United States
phone§949 238 8090
website§https://eledon.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Eledon Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS). The company's lead compound in development is tegoprubart, an anti-CD40L antibody with high affinity for CD40 Ligand, a biological target with therapeutic potential. It has a collaboration agreement with eGenesis, Inc. The company was formerly known as Novus Therapeutics, Inc. and changed its name to Eledon Pharmaceuticals, Inc. in January 2021. Eledon Pharmaceuticals, Inc. is headquartered in Irvine, California.
fullTimeEmployees§17
companyOfficers§[{'maxAge': 1, 'name': 'Dr. David-Alexandre C. Gros M.D., Ph.D.', 'age': 51, 'title': 'CEO & Non Independent Director', 'yearBorn': 1972, 'fiscalYear': 2022, 'totalPay': 807955, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Steven N. Perrin Ph.D.', 'age': 57, 'title': 'President, Chief Scientific Officer & Non Independent Director', 'yearBorn': 1966, 'fiscalYear': 2022, 'totalPay': 603898, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Paul Sean Little', 'age': 58, 'title': 'CFO & Principal Accounting Officer', 'yearBorn': 1965, 'fiscalYear': 2022, 'totalPay': 611713, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. John  Herberger', 'title': 'Vice President of Technical Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Bryan E. Smith J.D.', 'age': 43, 'title': 'General Counsel, Corporate Secretary & Chief Compliance Officer', 'yearBorn': 1980, 'fiscalYear': 2022, 'totalPay': 377136, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. David  Hovland Ph.D.', 'title': 'Chief Regulatory Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Eliezer  Katz F.A.C.S., FACS, M.D.', 'title': 'Chief Medical Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§4
payoutRatio§0.0
beta§1.512
currency§USD
dateShortInterest§1702598400
forwardEps§-1.39
pegRatio§0.02
exchange§NCM
quoteType§EQUITY
shortName§Eledon Pharmaceuticals, Inc.
longName§Eledon Pharmaceuticals, Inc.
firstTradeDateEpochUtc§1410960600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§2a495e4c-7ef2-3c4b-9213-71fbe48c07b6
gmtOffSetMilliseconds§-18000000
targetHighPrice§39.0
targetLowPrice§7.0
targetMeanPrice§15.6
targetMedianPrice§10.0
recommendationMean§1.7
recommendationKey§buy
numberOfAnalystOpinions§5
quickRatio§20.562
grossMargins§0.0
ebitdaMargins§0.0
trailingPegRatio§None
